Anish Patel, Chief Operating Officer of Enliven Therapeutics ($ELVN), sold common shares on the open market twenty times over the last year, totaling about $2.5 million. His most recent sale occurred on January 9, 2026. These $ELVN insider sales rank 3,045th among 11,678 individual insiders, below the average sale value of $8.6 million and average of 6.4 transactions. Patel made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 12, 2026 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | A | Stock Option (right to buy) | 120000 | $0.00 | 120,000.0000 | 62,093,795 | 9999.99% | 0.19% |
| Feb. 12, 2026 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | A | Common Stock | 20000 | $0.00 | 235,011.0000 | 62,093,795 | 9.30% | 0.03% |
| Jan. 9, 2026 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 48057 | $27.98 | 215,254.0000 | 62,093,795 | 18.25% | 0.08% |
| Jan. 9, 2026 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 243 | $28.50 | 215,011.0000 | 62,093,795 | 0.11% | 0.00% |
| Dec. 8, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 4958 | $20.76 | 265,016.0000 | 62,093,795 | 1.84% | 0.01% |
| Dec. 8, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 1705 | $21.78 | 263,311.0000 | 62,093,795 | 0.64% | 0.00% |
| Nov. 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 6054 | $17.35 | 270,587.0000 | 62,093,795 | 2.19% | 0.01% |
| Nov. 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 613 | $17.94 | 269,974.0000 | 62,093,795 | 0.23% | 0.00% |
| Oct. 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 6667 | $20.10 | 276,641.0000 | 62,093,795 | 2.35% | 0.01% |
| Sept. 8, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 6667 | $20.24 | 283,308.0000 | 47,072,532 | 2.30% | 0.01% |
| Aug. 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 405 | $18.93 | 289,975.0000 | 47,072,532 | 0.14% | 0.00% |
| Aug. 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 6262 | $18.20 | 290,380.0000 | 47,072,532 | 2.11% | 0.01% |
| July 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 6362 | $19.75 | 296,947.0000 | 47,072,532 | 2.10% | 0.01% |
| July 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 305 | $20.69 | 296,642.0000 | 47,072,532 | 0.10% | 0.00% |
| June 9, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 6607 | $20.33 | 303,369.0000 | 47,072,532 | 2.13% | 0.01% |
| June 9, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 60 | $21.16 | 303,309.0000 | 47,072,532 | 0.02% | 0.00% |
| May 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 104 | $19.87 | 309,976.0000 | 47,072,532 | 0.03% | 0.00% |
| May 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 6173 | $18.30 | 310,470.0000 | 47,072,532 | 1.95% | 0.01% |
| May 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 390 | $19.40 | 310,080.0000 | 47,072,532 | 0.13% | 0.00% |
| April 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 148 | $19.27 | 316,643.0000 | 47,072,532 | 0.05% | 0.00% |
| April 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 2763 | $18.29 | 316,791.0000 | 47,072,532 | 0.86% | 0.01% |
| April 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 3756 | $17.81 | 319,554.0000 | 47,072,532 | 1.16% | 0.01% |
| March 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 6667 | $21.44 | 323,310.0000 | 47,072,532 | 2.02% | 0.01% |
| Feb. 6, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | A | Stock Option (right to buy) | 171000 | $0.00 | 171,000.0000 | 47,072,532 | 9999.99% | 0.36% |
| Feb. 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 6667 | $21.93 | 329,977.0000 | 47,072,532 | 1.98% | 0.01% |
| Jan. 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | M | Common Stock | 9000 | $2.48 | 358,344.0000 | 47,072,532 | 2.58% | 0.02% |
| Jan. 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | M | Common Stock | 2000 | $2.48 | 349,344.0000 | 47,072,532 | 0.58% | 0.00% |
| Jan. 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 90 | $24.60 | 336,644.0000 | 47,072,532 | 0.03% | 0.00% |
| Jan. 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | M | Employee Stock Option (right to buy) | 10700 | $0.00 | 67.0000 | 47,072,532 | 99.38% | 0.02% |
| Jan. 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | M | Employee Stock Option (right to buy) | 2000 | $0.00 | 827.0000 | 47,072,532 | 70.75% | 0.00% |
| Jan. 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | M | Employee Stock Option (right to buy) | 9000 | $0.00 | 44,342.0000 | 47,072,532 | 16.87% | 0.02% |
| Jan. 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 6577 | $24.17 | 336,734.0000 | 47,072,532 | 1.92% | 0.01% |
| Jan. 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 1440 | $24.56 | 336,644.0000 | 47,072,532 | 0.43% | 0.00% |
| Jan. 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | M | Common Stock | 10700 | $1.12 | 347,344.0000 | 47,072,532 | 3.18% | 0.02% |
| Jan. 7, 2025 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 20260 | $24.15 | 338,084.0000 | 47,072,532 | 5.65% | 0.04% |
| Oct. 18, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 716 | $30.00 | 343,311.0000 | 48,267,458 | 0.21% | 0.00% |
| July 15, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 30978 | $25.05 | 345,574.0000 | 35,546,215 | 8.23% | 0.09% |
| July 12, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 17475 | $25.07 | 376,552.0000 | 35,546,215 | 4.43% | 0.05% |
| July 16, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 1547 | $25.01 | 344,027.0000 | 35,546,215 | 0.45% | 0.00% |
| June 6, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | M | Common Stock | 1133 | $2.48 | 395,160.0000 | 35,546,215 | 0.29% | 0.00% |
| June 6, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 1133 | $20.06 | 394,027.0000 | 35,546,215 | 0.29% | 0.00% |
| June 6, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | M | Employee Stock Option (right to buy) | 1133 | $0.00 | 53,342.0000 | 35,546,215 | 2.08% | 0.00% |
| May 14, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | M | Employee Stock Option (right to buy) | 1107 | $0.00 | 54,475.0000 | 35,546,215 | 1.99% | 0.00% |
| May 14, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | M | Common Stock | 1107 | $2.48 | 395,134.0000 | 35,546,215 | 0.28% | 0.00% |
| May 14, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 1107 | $25.00 | 394,027.0000 | 35,546,215 | 0.28% | 0.00% |
| May 9, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | M | Common Stock | 260 | $2.48 | 394,287.0000 | 35,546,215 | 0.07% | 0.00% |
| May 9, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | M | Employee Stock Option (right to buy) | 260 | $0.00 | 55,582.0000 | 35,546,215 | 0.47% | 0.00% |
| May 9, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 260 | $25.06 | 394,027.0000 | 35,546,215 | 0.07% | 0.00% |
| May 6, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | M | Employee Stock Option (right to buy) | 4875 | $0.00 | 55,842.0000 | 35,546,215 | 8.03% | 0.01% |
| May 6, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 4875 | $22.72 | 394,027.0000 | 35,546,215 | 1.22% | 0.01% |
| May 6, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | M | Common Stock | 4875 | $2.48 | 398,902.0000 | 35,546,215 | 1.24% | 0.01% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 17500 | $25.03 | 394,027.0000 | 35,546,215 | 4.25% | 0.05% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | M | Employee Stock Option (right to buy) | 14903 | $0.00 | 60,717.0000 | 35,546,215 | 19.71% | 0.04% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | M | Common Stock | 14903 | $2.48 | 411,527.0000 | 35,546,215 | 3.76% | 0.04% |
| April 8, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 544 | $19.40 | 396,624.0000 | 35,546,215 | 0.14% | 0.00% |
| April 8, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 4331 | $18.50 | 397,168.0000 | 35,546,215 | 1.08% | 0.01% |
| March 6, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 4875 | $15.64 | 401,499.0000 | 35,546,215 | 1.20% | 0.01% |
| Feb. 13, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | A | Stock Option (right to buy) | 185000 | $0.00 | 185,000.0000 | 35,546,215 | 9999.99% | 0.52% |
| Feb. 6, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | CHIEF OPERATING OFFICER | S | Common Stock | 4875 | $15.11 | 406,374.0000 | 35,546,215 | 1.19% | 0.01% |
| Jan. 22, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | Chief Operating Officer | S | Common Stock | 4875 | $15.14 | 411,249.0000 | 35,546,215 | 1.17% | 0.01% |
| Jan. 2, 2024 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | Chief Operating Officer | S | Common Stock | 11000 | $15.00 | 416,124.0000 | 35,546,215 | 2.58% | 0.03% |
| Dec. 29, 2023 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | Chief Operating Officer | S | Common Stock | 20 | $15.00 | 427,124.0000 | 0 | 0.00% | 0.00% |
| Dec. 28, 2023 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | Chief Operating Officer | S | Common Stock | 2520 | $15.08 | 427,144.0000 | 0 | 0.59% | 0.00% |
| Dec. 22, 2023 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | Chief Operating Officer | S | Common Stock | 983 | $15.03 | 429,766.0000 | 0 | 0.23% | 0.00% |
| Dec. 26, 2023 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | Chief Operating Officer | S | Common Stock | 102 | $15.01 | 429,664.0000 | 0 | 0.02% | 0.00% |
| April 4, 2023 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | Chief Operating Officer | A | Stock Option (right to buy) | 206000 | $0.00 | 206,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 23, 2023 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | Chief Operating Officer | A | Common Stock | 394027 | $0.00 | 430,749.0000 | 0 | 1073.00% | 0.00% |
| Feb. 23, 2023 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | Chief Operating Officer | A | Employee Stock Option (right to buy) | 2827 | $0.00 | 2,827.0000 | 0 | 9999.99% | 0.00% |
| Feb. 23, 2023 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | Chief Operating Officer | A | Employee Stock Option (right to buy) | 10767 | $0.00 | 10,767.0000 | 0 | 9999.99% | 0.00% |
| Feb. 23, 2023 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | Chief Operating Officer | A | Employee Stock Option (right to buy) | 75620 | $0.00 | 75,620.0000 | 0 | 9999.99% | 0.00% |
| Feb. 23, 2023 | Enliven Therapeutics, Inc. | $ELVN | Patel Anish | Chief Operating Officer | A | Common Stock | 36722 | $0.00 | 430,749.0000 | 0 | 9.32% | 0.00% |